Sorry, you need to enable JavaScript to visit this website.

Tolerability & Weight Gain | SYMTUZA® (darunavir/cobicistat/emtricitabine/tenofovir alafenamide)

Proven tolerability.

You deserve an HIV treatment you can stick with,
so talk with your doctor to see if SYMTUZA® is right for you.

A person with their arm around another person showing support

A closer look at tolerability

The tolerability of SYMTUZA® has been studied across 2 clinical trials.

Clinical trial information:

Over 1,100 people living with HIV were treated with SYMTUZA® in the trials.

  • People new to HIV treatment and people switching HIV treatments were a part of the trials.

Clinical trial results:



of patients in any of the 2 trials stopped taking SYMTUZA® due to side effects through 11 months.

  • There was a low incidence of HIV treatment-related weight gain across both studies through 11 months.
Trial graph icon

What are common
side effects of SYMTUZA®?

As with most medications, SYMTUZA® can cause side effects. The most common side effects occurring in at least 2% of patients taking SYMTUZA® were:

  • Diarrhea
  • Bone weakness
  • Rash
  • Nausea
  • Fatigue
  • Headache
  • Stomach problems
  • Gas

These are not all the possible side effects of SYMTUZA®. For more information, please refer to the Important Safety Information, including Boxed Warning, for SYMTUZA® and talk to your doctor.

Is weight gain a concern?

Weight concern icon

Weight gain can impact an individual's overall health, and it can be a concern when starting a new HIV treatment.*

Certain HIV treatments may cause more weight gain than other treatments. Some individuals can gain more weight on certain treatments than others. Always talk to your doctor before making any changes to your treatment regimen.


patients had to stop taking SYMTUZA® due to weight gain in two key studies.

*Long-term consequences of weight gain are not known. As research continues in this area, it's important to have ongoing conversations with your healthcare provider.

Across 2 clinical trials, one patient taking SYMTUZA® experienced treatment-related weight gain. The average weight gain over 48 weeks was between 3.13 lbs (1.42 kg) and 3.84 lbs (1.75 kg) in 1,125 patients in the SYMTUZA® group, and ~1 lb (.45 kg) for 741 patients in the control group. The long-term impact of SYMTUZA® on weight has not been studied in clinical trials.

Real people, real experiences

See what SYMTUZA® patients have to say about their HIV treatment.
Thumbnail of Danny, a SYMTUZA® patient

My doctor and I decide[d] SYMTUZA® was the right treatment for me...

Danny's story

Thumbnail of Brandon, a SYMTUZA® patient

I choose to continue to take
my medication, every day,
on time. Just one pill a day.

Brandon's story

Thumbnail of Helen, a SYMTUZA® patient

As a single mom working, and trying to do everything else, it's not easy to stop [and] take medication…I'm glad that my switch was right for me.

Helen's story

Thumbnail of Nathan, a SYMTUZA® patient

The medicine is doing what it's supposed to do, keeping my numbers where they are, and that's what's most important.

Nathan's story

Two people looking at each other and talking


Learn what the treatment plan is like with one pill, once-daily SYMTUZA®.

Learn more